



Better Health, Brighter Future

Takeda Pharmaceutical Company Limited
Christophe Weber, President & CEO
(TSE Code: 4502)
Contact: Global Finance, IR
(TEL: +81-3-3278-2306)

Takeda Information

September 11, 2018

(Correction) FY2018 Q1 DATA BOOK

This is for filing the partial correction of the FY2018 Q1 DATA BOOK, which was provided on July 31, 2018, as part of the supplementary materials for the financial statements for the same period. There are no changes to the financial figures stated in the financial statements.

1. Contents of corrections

FY2018 Q1 DATA BOOK, page 2, page 11, page 12 and page 13 (refer to next pages for details)

The corresponding parts are highlighted in yellow.

2. Reasons for corrections

Effective from FY2018, sales of products other than Oncology in Japan are now disclosed on a net basis, deducting items such as discounts and rebates, in alignment with the global managerial approach applied to individual product sales. The change in disclosure of individual products sales has been revised retrospectively, with FY2017 figures reclassified on a net basis to enable year-on-year comparisons. However, certain figures have not been correctly stated, therefore, they are amended as below (including figures less than 100 million yen).

As a result of this correction, product sales in Japan and overseas in FY2017 and FY2018 are now on a net basis, deducting items such as discounts and rebates.

◆ Prescription Drugs: Global major products' sales *1									(Billion JPY)
		FY15	FY16	FY17	FY17	FY18	YOY	FY18	FY18Q1
					Q1	Q1		Forecasts*3	Underlying Growth
Entyvio	U.S.	63.1	99.6	133.6	31.0	41.9	11.0	35.5%	39.3%
	EUCAN	21.9	39.5	60.2	13.5	17.2	3.7	27.5%	21.0%
	EM	1.3	4.0	7.5	1.4	2.2	0.7	50.4%	56.7%
	Total	86.2	143.2	201.4	45.9	61.3	15.4	33.6%	34.1%
Velcade	U.S.	131.6	112.9	113.7	30.7	26.2	-4.5	-14.7%	-12.1%
	Other than U.S.	30.4	24.7	23.6	5.5	5.2	-0.3	-6.1%	-3.4%
	Total	162.0	137.6	137.3	36.2	31.4	-4.8	-13.4%	-10.8%
Leuprorelin	Japan	53.8	48.6	47.6	11.0	10.5	-0.5	-4.7%	-4.7%
	U.S.	17.3	18.3	19.7	5.2	6.2	1.0	19.3%	19.9%
	EUCAN	35.3	31.1	34.5	8.1	8.4	0.4	4.7%	-1.1%
	EM	18.0	16.3	12.7	3.0	3.5	0.4	14.2%	10.6%
	Total	124.4	114.2	114.4	27.3	28.6	1.3	4.7%	2.7%
Azilva	Japan	59.0	66.9	73.0	16.8	19.4	2.6	15.5%	15.5%
Total	59.0	66.9	73.0	16.8	19.4	2.6	15.5%	15.5%	
Pantoprazole	U.S.	13.6	10.1	7.2	1.9	2.0	0.1	6.8%	9.3%
	EUCAN	43.4	30.5	30.6	7.9	7.2	-0.6	-8.0%	-13.6%
	EM	43.7	33.7	28.0	7.0	7.0	-0.0	-0.1%	0.8%
	Total	100.8	74.2	65.8	16.7	16.2	-0.5	-3.1%	-5.4%
Dexilant	U.S.	64.0	49.7	49.5	12.8	13.0	0.2	1.4%	4.2%
	EUCAN	5.4	5.7	6.4	1.4	1.7	0.3	18.7%	16.2%
	EM	5.7	7.3	9.9	2.1	2.7	0.6	30.4%	37.1%
	Total	75.1	62.6	65.7	16.3	17.4	1.1	6.6%	9.7%
Takecab	Japan	8.4	34.1	55.1	11.3	14.2	3.0	26.4%	26.4%
	Total	8.4	34.1	55.1	11.3	14.3	3.0	26.5%	26.5%
Nesina	Japan	36.9	32.9	30.1	7.3	7.8	0.5	6.8%	6.8%
	U.S.	5.3	5.2	6.0	1.2	1.2	-0.1	-6.9%	-3.9%
	EUCAN	3.5	6.1	9.0	2.0	2.6	0.6	28.7%	20.4%
	EM	3.3	4.9	8.6	1.4	2.6	1.2	84.3%	90.7%
	Total	48.9	49.1	53.7	11.9	14.1	2.2	18.2%	18.0%
Trintellix	U.S.	24.5	31.9	48.4	11.2	14.1	2.9	25.8%	29.4%
	Total	24.5	31.9	48.4	11.2	14.1	2.9	25.8%	29.4%
Uloric	U.S.	41.8	41.4	45.8	11.2	13.8	2.6	23.4%	27.1%
	EUCAN	0.7	0.7	0.8	0.2	0.2	0.0	4.2%	2.3%
	EM	-	0.1	0.3	0.1	0.1	0.0	17.1%	21.6%
	Total	42.5	42.2	46.8	11.4	14.1	2.6	23.1%	26.7%
Ninlaro	Japan	-	-	2.5	0.2	1.2	0.9	-	-
	U.S.	4.0	29.1	39.4	9.0	11.1	2.1	23.1%	26.8%
	EUCAN	-	0.2	4.0	0.6	1.6	0.9	147.5%	134.7%
	EM	0.0	0.1	0.6	0.1	0.1	0.0	39.7%	41.8%
	Total	4.1	29.4	46.4	10.0	14.0	4.0	39.6%	43.3%
Colcrys	U.S.	46.5	38.9	40.3	9.6	9.2	-0.4	-4.3%	-1.6%
	Total	46.5	38.9	40.3	9.6	9.2	-0.4	-4.3%	-1.6%
Adecetris	Japan	3.1	3.3	3.8	1.0	1.1	0.1	10.8%	10.8%
	Europe	17.4	17.5	20.1	4.7	5.5	0.8	17.7%	10.9%
	EM	7.2	9.3	14.3	3.6	4.3	0.7	20.0%	33.2%
	Total	27.6	30.1	38.5	9.3	11.0	1.7	17.8%	18.9%
Lansoprazole	Japan *2	41.3	8.1	4.7	1.5	0.9	-0.6	-42.2%	-9.1%
	U.S.	27.5	20.0	15.2	3.8	2.0	-1.7	-46.1%	-44.3%
	EUCAN	10.5	7.1	7.2	1.9	1.7	-0.2	-10.5%	-15.4%
	EM	10.2	9.2	9.7	2.5	2.4	-0.1	-4.5%	-5.8%
	Total	89.5	44.4	36.8	9.7	7.0	-2.7	-27.7%	-23.4%
Amitiza	U.S.	37.2	33.7	33.7	8.6	7.8	-0.8	-8.9%	-6.2%
	EUCAN	0.1	0.1	0.1	0.0	0.0	0.0	5.7%	3.1%
	EM	-	0.0	0.0	0.0	0.0	-0.0	-38.8%	-36.6%
	Total	37.3	33.8	33.8	8.6	7.9	-0.8	-8.9%	-6.2%
Iclusig	U.S.	-	2.7	20.4	4.7	6.3	1.6	34.2%	38.2%
	Other than U.S.	-	0.2	2.7	0.5	0.7	0.2	43.9%	48.0%
	Total	-	2.9	23.1	5.2	7.0	1.8	35.1%	39.1%
Alunbrig	U.S.	-	-	2.8	0.2	1.1	0.8	-	-
	Total	-	-	2.8	0.2	1.1	0.8	-	-

U.S.: United States, EUCAN: Europe and Canada, EM: Emerging Markets

*1 Sales amount includes royalty income and service income.

*2 Products were transferred to the Joint Venture with Teva in Japan (monotherapy in April 2016 and fixed dose combinations in May 2017).

Supply sales of these products to the JV is currently recognized.

*3 See page 15 for the profit forecast disclaimer.

➡ ± <10% ➡ +10%~20% ➡ +20%~30% ➡ +>30% ➡ -10%~20% ➡ -20%~30% ➡ ->30%

*4 Effective from FY2018, sales of certain products in Japan are now disclosed on a net basis, deducting items such as discounts and rebates, in alignment with the global managerial approach applied to individual product sales. The change in disclosure of individual product sales has been revised retrospectively, with prior year figures reclassified on a net basis to enable year-on-year comparisons. This reclassification has no impact on Takeda's financial statements and does not represent a correction of prior year figures.

◆ Prescription Drugs: Global major products' sales *1										(Billion JPY)
		Gross basis		Net basis					FY18Q1	
		FY15	FY16	FY17	FY17 Q1	FY18 Q1	YOY	FY18 Forecasts*3	Underlying Growth	
Entyvio	U.S.	63.1	99.6	133.6	31.0	41.9	11.0	35.5%		39.3%
	EUCAN	21.9	39.5	60.2	13.5	17.2	3.7	27.5%		21.0%
	EM	1.3	4.0	7.5	1.4	2.2	0.7	50.4%		56.7%
	Total	86.2	143.2	201.4	45.9	61.3	15.4	33.6%	↗ ↗ ↗	34.1%
Velcade	U.S.	131.6	112.9	113.7	30.7	26.2	-4.5	-14.7%		-12.1%
	Other than U.S.	30.4	24.7	23.6	5.5	5.2	-0.3	-6.1%		-3.4%
	Total	162.0	137.6	137.3	36.2	31.4	-4.8	-13.4%	↘ ↘ ↘	-10.8%
Leuprorelin	Japan	53.8	48.6	41.2	11.0	10.5	-0.5	-4.7%		-4.7%
	U.S.	17.3	18.3	19.7	5.2	6.2	1.0	19.3%		19.9%
	EUCAN	35.3	31.1	34.5	8.1	8.4	0.4	4.7%		-1.1%
	EM	18.0	16.3	12.7	3.0	3.5	0.4	14.2%		10.6%
Total	124.4	114.2	108.1	27.3	28.6	1.3	4.7%	→	2.7%	
Azilva	Japan	59.0	66.9	64.0	16.8	19.4	2.6	15.5%		15.5%
	Total	59.0	66.9	64.0	16.8	19.4	2.6	15.5%	→	15.5%
Pantoprazole	U.S.	13.6	10.1	7.2	1.9	2.0	0.1	6.8%		9.3%
	EUCAN	43.4	30.5	30.6	7.9	7.2	-0.6	-8.0%		-13.6%
	EM	43.7	33.7	28.0	7.0	7.0	-0.0	-0.1%		0.8%
	Total	100.8	74.2	65.8	16.7	16.2	-0.5	-3.1%	→	-5.4%
Dexilant	U.S.	64.0	49.7	49.5	12.8	13.0	0.2	1.4%		4.2%
	EUCAN	5.4	5.7	6.4	1.4	1.7	0.3	18.7%		16.2%
	EM	5.7	7.3	9.9	2.1	2.7	0.6	30.4%		37.1%
	Total	75.1	62.6	65.7	16.3	17.4	1.1	6.6%	→	9.7%
Takecab	Japan	8.4	34.1	48.5	11.3	14.2	3.0	26.4%		26.4%
	Total	8.4	34.1	48.5	11.3	14.3	3.0	26.5%	→	26.5%
Nesina	Japan	36.9	32.9	26.6	7.3	7.8	0.5	6.8%		6.8%
	U.S.	5.3	5.2	6.0	1.2	1.2	-0.1	-6.9%		-3.9%
	EUCAN	3.5	6.1	9.0	2.0	2.6	0.6	28.7%		20.4%
	EM	3.3	4.9	8.6	1.4	2.6	1.2	84.3%		90.7%
Total	48.9	49.1	50.2	11.9	14.1	2.2	18.2%	→	18.0%	
Trintellix	U.S.	24.5	31.9	48.4	11.2	14.1	2.9	25.8%		29.4%
	Total	24.5	31.9	48.4	11.2	14.1	2.9	25.8%	↗	29.4%
Uloric	U.S.	41.8	41.4	45.8	11.2	13.8	2.6	23.4%		27.1%
	EUCAN	0.7	0.7	0.8	0.2	0.2	0.0	4.2%		2.3%
	EM	-	0.1	0.3	0.1	0.1	0.0	17.1%		21.6%
	Total	42.5	42.2	46.8	11.4	14.1	2.6	23.1%	→	26.7%
Ninlaro	Japan	-	-	2.5	0.2	1.2	0.9	-		-
	U.S.	4.0	29.1	39.4	9.0	11.1	2.1	23.1%		26.8%
	EUCAN	-	0.2	4.0	0.6	1.6	0.9	147.5%		134.7%
	EM	0.0	0.1	0.6	0.1	0.1	0.0	39.7%		41.8%
Total	4.1	29.4	46.4	10.0	14.0	4.0	39.6%	↗ ↗ ↗	43.3%	
Colcrys	U.S.	46.5	38.9	40.3	9.6	9.2	-0.4	-4.3%		-1.6%
	Total	46.5	38.9	40.3	9.6	9.2	-0.4	-4.3%	↘ ↘	-1.6%
Adcetris	Japan	3.1	3.3	3.8	1.0	1.1	0.1	10.8%		10.8%
	Europe	17.4	17.5	20.1	4.7	5.5	0.8	17.7%		10.9%
	EM	7.2	9.3	14.3	3.6	4.3	0.7	20.0%		33.2%
	Total	27.6	30.1	38.5	9.3	11.0	1.7	17.8%	→	18.9%
Lansoprazole	Japan *2	41.3	8.1	4.6	1.5	0.9	-0.6	-42.2%		-9.1%
	U.S.	27.5	20.0	15.2	3.8	2.0	-1.7	-46.1%		-44.3%
	EUCAN	10.5	7.1	7.2	1.9	1.7	-0.2	-10.5%		-15.4%
	EM	10.2	9.2	9.7	2.5	2.4	-0.1	-4.5%		-5.8%
Total	89.5	44.4	36.8	9.7	7.0	-2.7	-27.7%	↘ ↘ ↘	-23.4%	
Amitiza	U.S.	37.2	33.7	33.7	8.6	7.8	-0.8	-8.9%		-6.2%
	EUCAN	0.1	0.1	0.1	0.0	0.0	0.0	5.7%		3.1%
	EM	-	0.0	0.0	0.0	0.0	-0.0	-38.8%		-36.6%
	Total	37.3	33.8	33.8	8.6	7.9	-0.8	-8.9%	→	-6.2%
Iclusig	U.S.	-	2.7	20.4	4.7	6.3	1.6	34.2%		38.2%
	Other than U.S.	-	0.2	2.7	0.5	0.7	0.2	43.9%		48.0%
	Total	-	2.9	23.1	5.2	7.0	1.8	35.1%	→	39.1%
Alunbrig	U.S.	-	-	2.8	0.2	1.1	0.8	-		-
	Total	-	-	2.8	0.2	1.1	0.8	-	↗ ↗ ↗	-

U.S.: United States, EUCAN: Europe and Canada, EM: Emerging Markets

*1 Sales amount includes royalty income and service income.

*2 Products were transferred to the Joint Venture with Teva in Japan (monotherapy in April 2016 and fixed dose combinations in May 2017).

Supply sales of these products to the JV is currently recognized.

*3 See page 15 for the profit forecast disclaimer.

↗ ± <10% ↗ +10%~20% ↗ ↗ +20%~30% ↗ ↗ ↗ +>30% ↘ -10%~20% ↘ ↘ -20%~30% ↘ ↘ ↘ ->30%

*4 Effective from FY2018, sales of certain products in Japan are now disclosed on a net basis, deducting items such as discounts and rebates, in alignment with the global managerial approach applied to individual product sales. The change in disclosure of individual product sales has been revised retrospectively, with prior year figures reclassified on a net basis to enable year-on-year comparisons. This reclassification has no impact on Takeda's financial statements and does not represent a correction of prior year figures.

Gross basis: discounts and rebates are not deducted (except FY2016 Oncology products in Japan are on net basis)

Net basis: discounts and rebates are deducted

<page 11 incorrect>

◆ Prescription Drugs: US major products' sales (in US\$) *¹							(Million US\$)	
	FY15	FY16	FY17	FY17 Q1	FY18 Q1	YOY		
Entyvio	524	913	1,202	278	387	109	39.3%	
Velcade	1,059	1,000	995	268	235	-32	-12.1%	
Trintellix	203	294	435	101	130	30	29.4%	
Uloric	347	380	411	101	128	27	27.1%	
Dexilant	530	457	445	115	120	5	4.2%	
Ninlaro	34	267	354	81	103	22	26.8%	
Colcrys	386	358	362	87	85	-1	-1.6%	
Amitiza	308	310	303	77	72	-5	-6.2%	
Iclusig	-	22	171	40	55	15	37.8%	
Prevacid (lansoprazole)	222	179	132	33	18	-15	-46.0%	
Alunbrig	-	-	25	2	10	8	-	

*1 Product sales (royalty income and service income are excluded).

<page 11 correct>

◆ Prescription Drugs: US major products' sales (in US\$) ^{*1}							(Million US\$)	
	Net basis						YOY	
	FY15	FY16	FY17	FY17 Q1	FY18 Q1			
Entyvio	524	913	1,202	278	387	109	39.3%	
Velcade	1,059	1,000	995	268	235	-32	-12.1%	
Trintellix	203	294	435	101	130	30	29.4%	
Uloric	347	380	411	101	128	27	27.1%	
Dexilant	530	457	445	115	120	5	4.2%	
Ninlaro	34	267	354	81	103	22	26.8%	
Colcrys	386	358	362	87	85	-1	-1.6%	
Amitiza	308	310	303	77	72	-5	-6.2%	
Iclusig	-	22	171	40	55	15	37.8%	
Prevacid (lansoprazole)	222	179	132	33	18	-15	-46.0%	
Alunbrig	-	-	25	2	10	8	-	

*1 Product sales (royalty income and service income are excluded).

Net basis: discounts and rebates are deducted

◆ Prescription Drugs: Japan major products' sales									
(Billion JPY)									
	Launched	Therapeutic Class	FY15	FY16	FY17	FY17 Q1	FY18 Q1	YOY	
Azilva * ¹	(12. 5)	Hypertension	59.0	66.9	64.0	16.8	19.4	2.6	15.5%
Takecab * ¹	(15. 2)	Acid-related Diseases	8.4	34.1	48.5	11.3	14.2	3.0	26.4%
Leuplin (leuprorelin)	(92. 9)	Prostate cancer, breast cancer and endometriosis	53.8	48.6	41.2	11.0	10.5	-0.5	-4.7%
Enbrel	(05. 3)	Rheumatoid arthritis	40.8	40.4	37.1	9.9	9.9	-0.0	-0.0%
Lotriga	(13. 1)	Hyperlipidemia	22.3	27.5	28.5	7.2	8.1	0.9	13.2%
Nesina * ¹	(10. 6)	Diabetes	36.9	32.9	26.6	7.3	7.8	0.5	6.8%
Vectibix	(10. 6)	Colorectal cancer	18.4	18.8	18.9	5.0	5.4	0.4	8.0%
Reminyl	(11. 3)	Alzheimer-type dementia	16.0	17.4	16.1	4.3	4.5	0.2	4.7%
Rozerem	(10. 7)	Insomnia	7.4	8.1	8.0	2.1	2.5	0.4	19.4%
Benet	(02. 5)	Osteoporosis	9.7	8.3	6.8	1.9	1.7	-0.2	-10.2%
Adcetris	(14. 4)	Malignant Lymphoma	3.1	3.3	3.8	1.0	1.1	0.1	10.8%
Ninlaro	(17. 5)	Multiple Myeloma	-	-	2.5	0.2	1.2	0.9	-
Azilect	(18. 6)	Parkinson's disease	-	-	-	-	0.3	0.3	-

*1 The figures include the amounts of fixed dose combinations and blister packs.

*2 Effective from FY2018, sales of certain products in Japan are now disclosed on a net basis, deducting items such as discounts and rebates, in alignment with the global managerial approach applied to individual product sales. The change in disclosure of individual product sales has been revised retrospectively, with prior year figures reclassified on a net basis to enable year-on-year comparisons. This reclassification has no impact on Takeda's financial statements and does not represent a correction of prior year figures.

◆ Prescription Drugs: Japan major products' sales

(Billion JPY)

Launched	Therapeutic Class	Gross basis		Net basis				YOY	
		FY15	FY16	FY17	FY17 Q1	FY18 Q1			
Azilva * ¹	(12. 5)	Hypertension	59.0	66.9	64.0	16.8	19.4	2.6	15.5%
Takecab * ¹	(15. 2)	Acid-related Diseases	8.4	34.1	48.5	11.3	14.2	3.0	26.4%
Leuplin (leuprorelin)	(92. 9)	Prostate cancer, breast cancer and endometriosis	53.8	48.6	41.2	11.0	10.5	-0.5	-4.7%
Enbrel	(05. 3)	Rheumatoid arthritis	40.8	40.4	37.1	9.9	9.9	-0.0	-0.0%
Lotriga	(13. 1)	Hyperlipidemia	22.3	27.5	28.5	7.2	8.1	0.9	13.2%
Nesina * ¹	(10. 6)	Diabetes	36.9	32.9	26.6	7.3	7.8	0.5	6.8%
Vectibix	(10. 6)	Colorectal cancer	18.4	18.8	18.9	5.0	5.4	0.4	8.0%
Reminyl	(11. 3)	Alzheimer-type dementia	16.0	17.4	16.1	4.3	4.5	0.2	4.7%
Rozerem	(10. 7)	Insomnia	7.4	8.1	8.0	2.1	2.5	0.4	19.4%
Benet	(02. 5)	Osteoporosis	9.7	8.3	6.8	1.9	1.7	-0.2	-10.2%
Adcetris	(14. 4)	Malignant Lymphoma	3.1	3.3	3.8	1.0	1.1	0.1	10.8%
Ninlaro	(17. 5)	Multiple Myeloma	-	-	2.5	0.2	1.2	0.9	-
Azilect	(18. 6)	Parkinson's disease	-	-	-	-	0.3	0.3	-

*1 The figures include the amounts of fixed dose combinations and blister packs.

*2 Effective from FY2018, sales of certain products in Japan are now disclosed on a net basis, deducting items such as discounts and rebates, in alignment with the global managerial approach applied to individual product sales. The change in disclosure of individual product sales has been revised retrospectively, with prior year figures reclassified on a net basis to enable year-on-year comparisons. This reclassification has no impact on Takeda's financial statements and does not represent a correction of prior year figures.

Gross basis: discounts and rebates are not deducted (except FY2016 Oncology products in Japan are on net basis)

Net basis: discounts and rebates are deducted

<page 13 incorrect>

◆ Consumer Healthcare: Japan major products' sales								(Billion JPY)
	FY15	FY16	FY17	FY17 Q1	FY18 Q1	YOY		
Alinamin tablet	25.2	24.1	25.1	7.4	5.3	-2.1	-28.5%	
Alinamin drink	14.9	16.1	14.7	3.9	3.6	-0.3	-6.8%	
Benza	9.8	10.0	9.3	1.2	1.0	-0.2	-15.9%	
Borraginol	4.5	4.5	4.5	1.1	0.9	-0.1	-12.8%	
Mytear	4.2	3.9	4.0	0.8	0.8	0.0	0.8%	
Midori-no-Shukan	1.1	2.7	3.4	0.9	0.7	-0.1	-13.2%	

*1 This table shows sales amount of Takeda Consumer Healthcare Company Limited (TCHC) in Japan. TCHC succeeded the business of Takeda's Japan Consumer Healthcare Business Unit (JCHBU), and started its business on April 1, 2017 as the new company.

*2 Effective from FY2018, sales of certain products in Japan are now disclosed on a net basis, deducting items such as discounts and rebates, in alignment with the global managerial approach applied to individual product sales. The change in disclosure of individual product sales has been revised retrospectively, with prior year figures reclassified on a net basis to enable year-on-year comparisons. This reclassification has no impact on Takeda's financial statements and does not represent a correction of prior year figures.

<page 13 correct>

◆ Consumer Healthcare: Japan major products' sales								(Billion JPY)
	Gross basis		Net basis					
	FY15	FY16	FY17	FY17 Q1	FY18 Q1	YOY		
Alinamin tablet	25.2	24.1	21.9	6.5	5.3	-1.2	-19.1%	
Alinamin drink	14.9	16.1	12.9	3.4	3.6	0.2	5.3%	
Benza	9.8	10.0	8.1	1.1	1.0	-0.1	-4.9%	
Borraginol	4.5	4.5	3.9	0.9	0.9	-0.0	-1.4%	
Mytear	4.2	3.9	3.5	0.7	0.8	0.1	14.0%	
Midori-no-Shukan	1.1	2.7	3.3	0.8	0.7	-0.1	-10.0%	

*1 This table shows sales amount of Takeda Consumer Healthcare Company Limited (TCHC) in Japan. TCHC succeeded the business of Takeda's Japan Consumer Healthcare Business Unit (JCHBU), and started its business on April 1, 2017 as the new company.

*2 Effective from FY2018, sales of certain products in Japan are now disclosed on a net basis, deducting items such as discounts and rebates, in alignment with the global managerial approach applied to individual product sales. The change in disclosure of individual product sales has been revised retrospectively, with prior year figures reclassified on a net basis to enable year-on-year comparisons. This reclassification has no impact on Takeda's financial statements and does not represent a correction of prior year figures.

Gross basis: discounts and rebates are not deducted
 Net basis: discounts and rebates are deducted

###